{"id":"W3213116899","doi":"10.1007/s12325-021-01944-y","title":"A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar","year":2021,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Nexus Clinical Research (Canada); Memorial University of Newfoundland","funders":"Amgen","keywords":"Infliximab; Medicine; Biosimilar; Rheumatoid arthritis; Pharmacology; Internal medicine; Monoclonal antibody; Tumor necrosis factor alpha; Immunology; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00186919,0.0002517177,0.001623917,0.00003947147,0.00004793565,0.00000303225,0.0005775704,0.0002554163,0.00004447995],"category_scores_gemma":[0.0005135731,0.00010671,0.0003597987,0.0003462653,0.0006414801,0.00007354793,0.0001292588,0.0002710758,1.731967e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002088232,"about_ca_system_score_gemma":0.0002662939,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000003992204,"about_ca_topic_score_gemma":0.00001491916,"domain_scores_codex":[0.9975705,0.0008230571,0.001044261,0.0003190812,0.00006071166,0.0001823816],"domain_scores_gemma":[0.9967089,0.001781244,0.0007674985,0.0005894878,0.000141462,0.00001139128],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000396736,0.0000955978,0.00003525594,0.03013265,0.000212214,9.729494e-8,0.00007719766,8.921572e-8,0.0000967455,0.0003633744,0.00003540918,0.9689117],"study_design_scores_gemma":[0.0002704224,0.0001421941,0.00004095245,0.0565202,0.0002229581,0.000008726101,0.00003609426,3.828095e-7,0.002478842,0.0001219853,0.9400237,0.000133568],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00002527306,0.9979408,0.0001730332,0.0001576978,0.0002339843,0.001389558,0.00004890363,0.000002981733,0.00002774281],"genre_scores_gemma":[0.00002695169,0.9961267,0.003386348,0.000273854,0.00001235238,0.0001100645,0.000009181025,0.0000119701,0.00004259464],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9687781,"threshold_uncertainty_score":0.4351509,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2992263050150922,"score_gpt":0.4893622988553286,"score_spread":0.1901359938402364,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}